Main Article Content
Abstract
Vitiligo is an idiopathic skin depigmentation disorder with clinical symptoms of macules and depigmented patches on the skin. Vitiligo is a multifactorial disorder associated with genetic and non-genetic. There are two types of vitiligo: non-segmental and segmental vitiligo. The type of vitiligo can be determined based on physical examination and affects the disease course, prognosis, and therapy response. Vitiligo management is still a challenge on its own because the etiology is not clear, and many factors must be considered in the vitiligo treatment. Vitiligo management greatly varies depending on the activity and the disease expansion. The goals of vitiligo treatment include stopping disease progression, increasing repigmentation, and preventing recurrence. Vitiligo therapy options vary widely, but none have been effective in treating vitiligo with a high recurrence rate. One of the vitiligo treatment options is systemic corticosteroids given in pulse doses bringing the effect of decreasing the vitiligo progression and minimizing side effects. This literature review aims to determine the use of pulse dose corticosteroid therapy in vitiligo.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.